Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) was upgraded by equities researchers at HC Wainwright to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks reports. A number of other brokerages also recently issued reports on GLUE. Guggenheim reissued a “buy” rating and issued a $28.00 price objective […]

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 245.30% from the company’s previous close. […]

Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 74.98% from the company’s previous close. Several other […]